(Reuters) -Johnson & Johnson ( JNJ ) said on Friday it will discontinue a mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.

The decision to discontinue the study was part of a reprioritization of the company's communicable diseases research and development portfolio, J&J said.

In another mid-stage study, six of 10 participants on the drug mosnodenvir showed no detectable dengue virus in their blood after being exposed to the pathogen.